Clinical Trials Browser

Phase 3 × Carcinoma, Hepatocellular × spartalizumab × Clear all

NCT03744247 2019-05-02

Lenvatinib Plus PD-1 Antibody Versus Lenvtinib Alone for Advanced HCC

Phase 3 Withdrawn

Gastrointestinal

Carcinoma, Hepatocellular

NCT03791918 2019-05-02

Lenvatinib Plus PD-1 Antibody vs TACE for Intermediate-stage HCC Beyond Up-to-seven Criteria

Phase 3 Withdrawn

Gastrointestinal

Carcinoma, Hepatocellular